The Meb Faber Show: “A Generational Buying Opportunity in Biotech May Be Happening Now”
The Meb Faber Show: “A Generational Buying Opportunity in Biotech May Be Happening Now”
Today’s guest is Chris Clark. Chris was a biotech PM for 10 years at RS Investments, managing $4.5 billion.
In today’s episode, Chris discusses the complexities of the biotech sector, which has suffered a dramatic drawdown the past few years. He begins by explaining how biotech works, why it’s such a unique sector, and what has kept investors and companies frozen the past few years. He also explains the different perspectives of venture capitalists and public market investors, the current regulatory environment and how AI may reshape drug development.
To see links or read the transcript of the episode, visit us at: https://www.themebfabershow.com/episo…
(0:00) Starts
(1:20) Biotech industry overview
(18:09) Can you be a quant in biotech?
(25:09) Biotech market cap distribution and benchmark underweighting
(34:47) Addressing biotech volatility, market outlook, and non-pro investing tips
(47:02) Private vs. public biotech investments
(1:01:32) Global biotech markets (China)
(1:09:48) AI and regulatory impact on biotech
(1:21:14) US healthcare spending
(1:33:48) Chris’ most memorable investment
—-
Have questions? Reach out to us any time at info@cambriainvestments.com.
—– Follow Meb:
Twitter: https://twitter.com/MebFaber
LinkedIn: https://www.linkedin.com/in/mebanefaber/
Website: http://mebfaber.com/
20251112
